glp-1 agonists medications for Weight Loss How Three Types of GLP-1

Meal composition and timing may affect postprandial metabolism

Introduction Recent pharmaceutical developments with Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA), such as incretin-based and glucagon-like peptide-1 receptor agonists, have significantly advanced medical treatments for obesity [1]

GLP-1 has a direct CVD protective effect through its action on both the heart and kidney

For broader context on nutritional modulation of GLP-1 secretion see this review: Nutrition & Metabolism review

Discontinued formulations Efpeglenatide and taspoglutide Efpeglenatide and taspoglutide were once-promising, long-acting GLP-1 receptor agonists developed for the treatment of T2DM, both designed for once-weekly administration

These products are not FDA-approved drugs